TapImmune CEO Glynn Wilson to Chair Panel Discussion on the Future of Combination Therapies in Oncology

JACKSONVILLE, Fla., July 18, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women's cancers, announced today that Dr. Glynn Wilson, Chairman and CEO of TapImmune, will chair a panel discussion on the future of combination therapies in oncology at a meeting of the Northeast Chapter of BioFlorida on Wednesday, July 19, 2017. The meeting is to be held at the University of Florida's Health Proton Therapy Institute in Jacksonville, Florida.

Details of the panel discussion are as follows:

About TapImmune, Inc.
TapImmune, Inc. is a leader in the immunotherapy of woman's cancers advancing multiple Phase 2 and Phase 1b/2 clinical studies for the treatment of ovarian and breast cancer. The company's peptide- or nucleic acid-based immunotherapeutic products comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company's technologies may be used as stand-alone medications or in combination with current treatment modalities.

For additional information, please call toll­ free at 1­-866­-359-7541 or visit: tapimmune.com

To receive future press releases via email, please visit:
https://tapimmune.com/investors/email-alerts/

Follow us on Twitter @Tapimmune_Inc, or follow us on Facebook.

Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The company assumes no obligation to update the forward-looking statements. 

View original content with multimedia:http://www.prnewswire.com/news-releases/tapimmune-ceo-glynn-wilson-to-chair-panel-discussion-on-the-future-of-combination-therapies-in-oncology-300489377.html

SOURCE TapImmune Inc.